Since GBA mutations lead to accumulation of glucosylceramide and possible relative reduction in ceramide, it has been hypothesized that reduced ceramide may also contribute to the pathogenesis in GBA-related PD. This evidence concerns the gene GBA1 and Parkinson disease.